### Edgar Filing: BARR PHARMACEUTICALS INC - Form S-8 POS

## BARR PHARMACEUTICALS INC

Form S-8 POS February 18, 2009

> As filed with the Securities and Exchange Commission on February 18, 2009 Registration No. 333-102070 \_\_\_\_\_\_

> > SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Post-Effective Amendment No. 1 to Form S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

BARR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization) Identification Number)

42-1612474

400 Chestnut Ridge Road Woodcliff Lake, New Jersey 07677-7668 (201) 930-3300 (Address of Principal Executive Offices Including Zip Code)

Barr Laboratories, Inc. 2002 Stock Option Plan for Non-Employee Directors

(Full title of the plans)

William S. Marth c/o Teva Pharmaceuticals USA, Inc. 1090 Horsham Road North Wales, Pennsylvania 19454-1090 (215) 591-3000

(Name, address, including zip code, and telephone number, including area code, of agent for service)

With copies to:

Peter H. Jakes Jeffrey S. Hochman Willkie Farr & Gallagher LLP 787 Seventh Avenue New York, New York 10019-6099 (212) 728-8000

DEREGISTRATION OF UNSOLD SECURITIES

#### Edgar Filing: BARR PHARMACEUTICALS INC - Form S-8 POS

The shares of common stock of Barr Pharmaceuticals, Inc., par value \$0.01 per share (the "Common Stock"), giving effect to the 3-for-2 stock splits of the Common Stock in March 2003 and March 2004, previously registered for sale to the public and remaining unsold under this Registration Statement are hereby withdrawn from registration.

#### SIGNATURES

Pursuant to the requirements of the Securities Act, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Woodcliff Lake, State of New Jersey, February 18, 2009.

Barr Pharmaceuticals, LLC, as the successor entity by merger to BARR PHARMACEUTICALS, INC.

By: /s/ William S. Marth

William S. Marth

President (Chief Executive Officer)

Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment No. 1 to the Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Richard S. Egosi

Name	Title(s)	D
		_
/s/ William S. Marth	President (Chief Executive Officer) and Manager	Februar
William S. Marth		
/s/ Deborah A. Griffin	Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)	Februar
Deborah A. Griffin		
/s/ Richard S. Egosi	Manager	Februar

# Edgar Filing: BARR PHARMACEUTICALS INC - Form S-8 POS